Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to -$4.3 million.

  • Amphastar Pharmaceuticals' Cash from Financing Activities rose 8094.76% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.9 million, marking a year-over-year increase of 1199.65%. This contributed to the annual value of -$81.0 million for FY2024, which is 11782.74% down from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Cash from Financing Activities stood at -$4.3 million, which was up 8094.76% from -$30.2 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Cash from Financing Activities peaked at $428.1 million during Q2 2023, and registered a low of -$47.1 million during Q4 2023.
  • For the 5-year period, Amphastar Pharmaceuticals' Cash from Financing Activities averaged around $13.7 million, with its median value being -$13.5 million (2023).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Cash from Financing Activities tumbled by 373083.7% in 2021 and then skyrocketed by 4316951.71% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$8.7 million in 2021, then crashed by 85.86% to -$16.2 million in 2022, then tumbled by 191.32% to -$47.1 million in 2023, then increased by 28.12% to -$33.8 million in 2024, then soared by 87.16% to -$4.3 million in 2025.
  • Its Cash from Financing Activities was -$4.3 million in Q3 2025, compared to -$30.2 million in Q2 2025 and -$14.5 million in Q1 2025.